Holen Sie sich die Stockscreener-App
1.57
14.67%
-0.27
Handel nachbörslich:
1.56
-0.01
-0.64%
Schlusskurs vom Vortag:
$1.84
Offen:
$1.85
24-Stunden-Volumen:
666.18K
Relative Volume:
0.60
Marktkapitalisierung:
$4.25M
Einnahmen:
$32.96M
Nettoeinkommen (Verlust:
$-4.23M
KGV:
-0.0101
EPS:
-155.3294
Netto-Cashflow:
$-14.00M
1W Leistung:
-21.50%
1M Leistung:
-26.60%
6M Leistung:
-50.47%
1J Leistung:
-99.15%
1-Tages-Spanne:
$1.50
$1.89
1-Wochen-Bereich:
$1.50
$3.90
52-Wochen-Spanne:
$1.50
$248.00
Sunshine Biopharma Inc Stock (SBFM) Company Profile
Firmenname
Sunshine Biopharma Inc
Sektor
Telefon
954-515-0810
Adresse
333 LAS OLAS WAY, FORT LAUDERDALE
Vergleichen Sie SBFM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SBFM
Sunshine Biopharma Inc
|
1.57 | 4.25M | 32.96M | -4.23M | -14.00M | -155.33 |
|
ZTS
Zoetis Inc
|
151.73 | 67.94B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.72 | 46.50B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
9.89 | 44.66B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.80 | 15.81B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
292.46 | 13.14B | 2.76B | 1.11B | 898.10M | 22.77 |
Sunshine Biopharma Inc Aktie (SBFM) Neueste Nachrichten
Sunshine Biopharma (NASDAQ:SBFMW) Trading Down 10.9% – Here’s Why - Defense World
Sunshine Biopharma stock hits 52-week low at $1.85 amid steep decline By Investing.com - Investing.com South Africa
Sunshine Biopharma Closes $2.46 Million Direct Offering - TipRanks
Sunshine Biopharma Closes $2.5 Million Direct Offering - MarketScreener
Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering - ACCESS Newswire
Sunshine Biopharma Raises Fresh Capital: $2.46M from Institutional Investors - Stock Titan
SEC Form 424B5 filed by Sunshine Biopharma Inc. - Quantisnow
Sunshine Biopharma stock hits 52-week low at $1.85 amid steep decline - Investing.com India
Sunshine Biopharma’s K1.1-mRNA-LNP shows promise in HCC mouse model - BioWorld MedTech
The time has not yet come to remove your chips from the table: Sunshine Biopharma Inc (SBFM) - Sete News
Sunshine Biopharma Reports 78% Revenue Growth and Key Developments in 2022 - TipRanks
Sunshine Biopharma (SBFM) Secures $2.46 Million in Direct Stock Offering - GuruFocus
Sunshine Biopharma secures $2.46 million in stock offering - Investing.com
Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules - ACCESS Newswire
$2.46M Institutional Investment: Sunshine Biopharma Announces Strategic Direct Offering - Stock Titan
Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug - Benzinga
Biotech Stock Sunshine Biopharma Inc. (NASDAQ:SBFM) Makes NASDAQ Top Gainer List on News - Investorideas.com
Sunshine Biopharma (SBFM) Announces Promising Results for Liver Cancer Treatment - GuruFocus
Sunshine Biopharma reports progress in liver cancer treatment - Investing.com India
Sunshine Biopharma Completes Additional Studies of mRNA Therapy for Liver Cancer; Shares Up Pre-Bell - MarketScreener
Pre-market Movers: IBG, JYD, SBFM, SPWH, RSLS… - RTTNews
Revolutionary mRNA Treatment Succeeds Against Deadly Liver Cancer in Latest Trial - Stock Titan
Sunshine Biopharma (SBFM) Reports Increased Revenue Despite Net Loss - GuruFocus
Sunshine Biopharma (SBFM) Reports 2024 Financial Highlights - GuruFocus
Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year - ACCESS Newswire
Sunshine Biopharma Inc. SEC 10-K Report - TradingView
Sunshine Biopharma (SBFM) Stock Soars In Pre-Market Trading - Stocks Telegraph
Sunshine Biopharma Inc expected to post earnings of 11 cents a shareEarnings Preview - TradingView
Sunshine Biopharma signs agreement for rights to market two generic antibiotics - Yahoo Finance
Sunshine Biopharma to market new antibiotics in Canada By Investing.com - Investing.com Australia
Sunshine Biopharma acquires marketing rights for two new antibiotics in Canada - MSN
Sunshine Biopharma to market new antibiotics in Canada - Investing.com India
Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada - Yahoo Finance
Major Antibiotics Deal: Sunshine Biopharma Expands Portfolio in Billion-Dollar Market - Stock Titan
Sunshine Biopharma stock hits 52-week low at $2.01 By Investing.com - Investing.com Australia
Sunshine Biopharma stock hits 52-week low at $2.01 - Investing.com India
Sunshine Biopharma (NASDAQ:SBFMW) Trading Down 0.5% – Should You Sell? - Defense World
Sunshine Biopharma expands with new gastrointestinal drug By Investing.com - Investing.com Canada
Sunshine Biopharma expands with new gastrointestinal drug - Investing.com India
Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market - ACCESS Newswire
Sunshine Biopharma stock hits 52-week low at $2.09 By Investing.com - Investing.com Australia
Sunshine Biopharma stock hits 52-week low at $2.09 - Investing.com India
A Look at Sunshine Biopharma Inc (SBFM) Shares in the Recent Past Indicates Growth - SETE News
Sunshine Biopharma (NASDAQ:SBFMW) Trading 30% Higher – Should You Buy? - Defense World
Sunshine Biopharma Announces Reverse Stock Split - ACCESS Newswire
Sunshine Biopharma Launches Two New Generic Prescription Drugs - ACCESS Newswire
Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R) - ACCESS Newswire
Sunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54% - ACCESS Newswire
Sunshine Biopharma (NASDAQ:SBFM) Stock Quotes, Forecast and News Summary - Benzinga
Who’s Hired? Haruvi Returns For A Second Term As AAM Chair - News & Insights
Sunshine Biopharma launches Olanzapine and Olanzapine ODT - Indian Pharma Post
Finanzdaten der Sunshine Biopharma Inc-Aktie (SBFM)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):